Compare Boston Scientific Corporation (BSX) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs iShares Core MSCI Emerging Markets ETF — how do they compare? Boston Scientific Corporation trades at $43.25 (market cap $66.37B), while iShares Core MSCI Emerging Markets ETF trades at $79.6. The key difference: iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | IEMG | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $108.14 | $86.00 |
52-Week Low | $42.63 | $59.90 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
IEMG is trading at $78.49, down 3.49% over the past 24 hours amid a bearish technical signal. The ETF has delivered strong performance with a 35% surge over the past year, driven by its 40% technology weighting and exposure to South Korean and Taiwanese semiconductor stocks. Recent news highlights record inflows into emerging markets and IEMG's cost advantage over competitors like EEM with its 0.09% expense ratio.
The outlook for IEMG remains mixed with attractive emerging market valuations and AI-driven growth potential balanced against elevated volatility and geopolitical risks. While the fund offers diversified exposure to fast-growing economies, investors face concentration risks in tech stocks and potential headwinds from US-China trade tensions that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
